Eli Lilly and Company: Endometrial Neoplasms trials
The registry lists 11 Endometrial Neoplasms studies with Eli Lilly and Company as lead sponsor. 4 are open to participants now and 1 have results posted.
Phase 1 8Phase 2 4Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 1
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
- A Trial for Patients With Advanced/Recurrent Endometrial CancerCompletedNCT00377520Phase 2Results posted
- A Study of LY4175408 in Participants With Advanced CancerActive, not recruitingNCT07046923Phase 1
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1
- A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue TreatmentCompletedNCT00190697Phase 4
- Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial CancerCompletedNCT00003669Phase 2